ZeroTLR

#TRILUMINATE #TEER #TriClip RCT @ACCinTouch #ACC2023 late breaker by @psorajja No diff vs GDMT in ☠️🏩but ⬆️KCCQ ⬇️TR at 1y. Pts DO feel better! Honored to be in this trial and my 1st paper @NEJM! @hahn_rt @caresans26 @SachinGoelMD @mirvatalasnag @KHERA_MD @ParasuramMD

85y♂️ NSTEMI, 5y ago had TAVI in embolized TAVI during same procedure. Today, PCI to RCA & angiogram to LM done (LAD non-viable). 5Fr RJC advanced over wire between the valves and aortic wall. Spacious STJ was helpful.

#CRT2023 @CathElectroSurg on multivariate prediction model for coronary obstruction in native & ViV #TAVR — ✅ measure cusp ht:coronary ht/sinus ht ✅ measure VTC / VTSTJ (<4mm = ⬆️risk) ✅ measure leaflet calcium volume (>600mm3 = ⬆️risk) ➡️ sig improved sens/spec @CRT_meeting

#CRT2023 PCI vs CABG for LM dz w & w/out DM 25% DM DM pts more likely to have higher Syntax & co-morbidities PEP: all cause ☠️ SEP: CVS & non-CVS ☠️,stroke, peri-procedural & spontaneous MI No difference in PEP btwn revasc strategy ⬆️ spontaneous MI & repeat revasc w PCI

Hypoattenuated Leaflet Thickening (HALT) Operative view of Sapien 3 implanted 6 months prior with #HALT of right and noncoronary leaflet. #TAVR

@JoaoLCavalcante #CRT23 Bicuspid Anatomy for TAVR The more calcification raphe leaflet LVOT worse mortality Shorter membranous septal length in BAV High LV-Ao angle >60 deg Concomitant coronary anomalies & coronary heights #Imaging 🔑 to BAV pt selection for TAVR

Current hs-cTn assays are highly valuable for rule-out of AMI. This comes at the price of specificity, unless serial assessments are made. However, serial testing does not differentiate Type 1 from Type 2 AMI and, therefore, robust clinical assessment remains crucial. #CRT2023

First-in-human TELLTALE-BASILICA @StFrancis_LI! TELLTALE is the first and only dedicated system for transcatheter electrosurgical leaflet modification. Life is so much easier with dedicated devices - BASILICA took only a few minutes and the patient did great! Details at #crt2023

✨Glad to share at #CRT2023 our @MonteHeart experience on Prophylactic IABP in TF-TAVI 🌐Out now @EuroInterventio: eurointervention.pcronline.com/article/prophy… @azeemlatib @jgranadacrf @m_assafin @leoneppmd @MatteoMSturla @CurioJonathan @SebLudwig1 @SpringMD @MontefioreNYC @EinsteinMed @crfheart

Amazing #ValvePPM app by @bapat_savrtavr @hahn_rt @PPibarot on avoiding PPM and check valve function with ref EOA in AVR MVR #TAVR. Must download now to benefit your pts! @JoaoLCavalcante @mirvatalasnag @PCRonline @crfheart @igeorge1975 @AATSHQ @STS_CTsurgery @EACTS @escardio

1/Excited to share our recent @ccijournal publication on the incidence & distribution of missed paravalvular regurgitation (PVR) led by Dr. Syed Zaid @AhmedHaniyehMD & @MalikMD10 & huge thanks to @hasan_ahmadMD @GoldbergJBCTMD @GilbertTangMD 🔗onlinelibrary.wiley.com/doi/abs/10.100… A 🧵...

Don’t miss @NytvL today #NewYork Transcatheter Valve. World class speakers, 6 live #TAVR #TEER #TMVR cases! @MountSinaiHeart @MountSinaiNYC @IcahnMountSinai @DrSaminSharma @DoctorKini @Drroxmehran @georgedangas @KHERA_MD @ParasuramMD @StamLerakis @DrDavidReich @BethOliverVP

In this multicentre, propensity-matched comparison of the self-expanding ACURATE neo2 and the balloon-expandable SAPIEN 3 Ultra prostheses, the authors found comparably good short-term outcomes but some differences in device success and paravalvular leak. ow.ly/wsyG50LunWt

80y♂️ severe AS heavily ca EF35%, RBBB, LAD prox-mid 90% calcified lesion. PCI to LAD then #TAVR with #evolute_29. Pre&post🎈. #commisural_alignment #cusp_overlap. shallow implant. No ECG↔️,PG3, NO AI. Easy coronary re-access. @mirvatalasnag @ZeroTLR @rashaalbawardy @DrAlsaiediAB

Honored to present at #HongKongValves2022 alongside a great lineup of speakers. Hope to go back to my birthplace next year in person! #TAVR #FixTR #TMVR @bapat_savrtavr @TsuyoshiKaneko1 @vonBardelebenRS @CathElectroSurg @m_taramasso @hahn_rt @mirvatalasnag @azeemlatib

@BaoGTran @CirujaBarbosa @EACTS @JACCJournals @Pooh_Velagapudi @heartsurgeryuk @SusheelKodaliMD “only 51% of patients met all inclusion and exclusion criteria of the PARTNER 3 (The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low-Risk Patients w Aortic Stenosis) trial (3) & 41% had a clinical variable that was excluded from TAVR v SAVR trials”

@BaoGTran @CirujaBarbosa @EACTS But just take a look of both LR trials and the exclusion criteria ( cherry 🍒 picking?) , they don’t reflect regular clinical practice #TAVR /#SAVR Recommend lecture: @jaccjournals jacc.org/doi/10.1016/j.… @Pooh_Velagapudi @heartsurgeryuk @SusheelKodaliMD

Mortality at 1 yr after TAVI in LOW RISK PATIENTS. It doesn’t looks recommended. ⁦@EACTS⁩

@anvoramd @Abiomed Patients will ask Cardiologist about that “thing” for their case, because it will improve their survival rates as the different stories published reflect, in the same way they ask for other devices/ techniques/technologies. Take a look👀: abiomed.com/patients-and-c…

Interesting direct-to-consumer marketing by @Abiomed at Boston Logan airport. Though I wonder who the “consumers” are - patients or cardiologists? TCT was a few weeks ago…

@GilbertTangMD @TCTConference @NEJM @Drroxmehran @georgedangas @djc795 @mirvatalasnag @SachinGoelMD @PPibarot @lamelaspablo @TCTMD @KendraGrubb @PK_parasu @KHERA_MD @RodrigoBagur @JasonFoerst NEGATIVE trial. Therefore subgroups are hypothesis generating at best. Second, no correction made for statistical chance so only point estimates for the many subgroups given in NEJM. Presentations and ads don’t undergo the same rigour, unfortunately, so a p value has snuck in.

84y♀️ sever AS, perim 62,area 300, SOV 26.6, LM 6.8. #lifetime_management #TAVR @Medtronic #evolute 23mm #cusp_overlap #commisural_alignment MPG 4, No AI, no ECG change @DrAlsaiediAB @MogneeA @rashaalbawardy @bogamisa @AlrahimiJ @TAVRBot @mirvatalasnag @GilbertTangMD @colum_owens